 Tomomi Yamamoto
Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 10 | 2023 | 420 | 2.240 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 7 | 2023 | 76 | 1.910 |
Why?
| | Xenopus Proteins | 9 | 2013 | 67 | 1.430 |
Why?
| | Oocytes | 9 | 2014 | 190 | 1.390 |
Why?
| | Phthalazines | 2 | 2019 | 47 | 0.850 |
Why?
| | Cystadenocarcinoma, Serous | 4 | 2023 | 49 | 0.780 |
Why?
| | Piperazines | 2 | 2019 | 316 | 0.730 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 87 | 0.680 |
Why?
| | Xenopus laevis | 9 | 2014 | 128 | 0.630 |
Why?
| | Protein Phosphatase 2 | 2 | 2014 | 35 | 0.570 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2023 | 671 | 0.490 |
Why?
| | Cell Cycle Proteins | 5 | 2013 | 563 | 0.480 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2014 | 45 | 0.470 |
Why?
| | RNA, Messenger, Stored | 1 | 2013 | 13 | 0.460 |
Why?
| | Xenopus | 3 | 2011 | 104 | 0.430 |
Why?
| | Drosophila Proteins | 1 | 2014 | 171 | 0.420 |
Why?
| | Protein Biosynthesis | 2 | 2013 | 395 | 0.420 |
Why?
| | Cell Nucleus | 1 | 2014 | 577 | 0.380 |
Why?
| | Cell Line, Tumor | 9 | 2023 | 2837 | 0.340 |
Why?
| | Proto-Oncogene Proteins c-mos | 2 | 2005 | 5 | 0.330 |
Why?
| | Wnt Signaling Pathway | 2 | 2019 | 150 | 0.310 |
Why?
| | Mitosis | 4 | 2014 | 172 | 0.290 |
Why?
| | DNA Repair | 2 | 2022 | 197 | 0.270 |
Why?
| | Ubiquitin-Protein Ligase Complexes | 1 | 2005 | 7 | 0.260 |
Why?
| | Cyclin B | 1 | 2005 | 14 | 0.260 |
Why?
| | Ovum | 1 | 2005 | 30 | 0.260 |
Why?
| | Breast Neoplasms | 4 | 2019 | 1959 | 0.260 |
Why?
| | DNA Damage | 2 | 2022 | 356 | 0.260 |
Why?
| | BRCA2 Protein | 2 | 2022 | 44 | 0.230 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 453 | 0.230 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2023 | 50 | 0.220 |
Why?
| | Claudin-4 | 1 | 2022 | 9 | 0.210 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 15 | 0.210 |
Why?
| | Animals | 17 | 2023 | 33152 | 0.210 |
Why?
| | Cell Cycle | 1 | 2005 | 547 | 0.210 |
Why?
| | Antineoplastic Agents | 2 | 2023 | 1967 | 0.200 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2020 | 1161 | 0.200 |
Why?
| | Phosphorylation | 4 | 2014 | 1622 | 0.190 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 40 | 0.190 |
Why?
| | Female | 18 | 2023 | 61268 | 0.180 |
Why?
| | Epoxy Compounds | 1 | 2020 | 33 | 0.180 |
Why?
| | Wnt3A Protein | 1 | 2019 | 8 | 0.180 |
Why?
| | Wnt4 Protein | 1 | 2019 | 18 | 0.180 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2020 | 47 | 0.180 |
Why?
| | Rad51 Recombinase | 1 | 2019 | 13 | 0.180 |
Why?
| | Acyltransferases | 1 | 2019 | 52 | 0.180 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2013 | 406 | 0.170 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 360 | 0.170 |
Why?
| | Histocompatibility Antigens | 1 | 2019 | 102 | 0.170 |
Why?
| | Indazoles | 1 | 2019 | 60 | 0.170 |
Why?
| | Protein Binding | 3 | 2016 | 1969 | 0.170 |
Why?
| | Heterografts | 1 | 2019 | 129 | 0.170 |
Why?
| | Immunoprecipitation | 2 | 2016 | 161 | 0.170 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2019 | 99 | 0.160 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2435 | 0.160 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 333 | 0.160 |
Why?
| | Progesterone | 2 | 2011 | 242 | 0.160 |
Why?
| | Piperidines | 1 | 2019 | 171 | 0.160 |
Why?
| | Amino Acid Sequence | 5 | 2013 | 2063 | 0.150 |
Why?
| | Polyadenylation | 1 | 2017 | 38 | 0.150 |
Why?
| | Sequence Homology, Amino Acid | 3 | 2013 | 367 | 0.150 |
Why?
| | Fatty Acids | 1 | 2020 | 403 | 0.150 |
Why?
| | Indoles | 1 | 2019 | 311 | 0.150 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 14 | 0.140 |
Why?
| | Up-Regulation | 1 | 2020 | 862 | 0.140 |
Why?
| | Receptors, Estrogen | 2 | 2016 | 386 | 0.140 |
Why?
| | Oogenesis | 2 | 2013 | 27 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2017 | 181 | 0.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2016 | 449 | 0.140 |
Why?
| | Mitochondrial Proteins | 1 | 2017 | 224 | 0.130 |
Why?
| | Artifacts | 1 | 2016 | 125 | 0.130 |
Why?
| | RNA-Binding Proteins | 2 | 2016 | 369 | 0.130 |
Why?
| | Binding Sites | 2 | 2016 | 1221 | 0.130 |
Why?
| | Humans | 19 | 2023 | 118268 | 0.130 |
Why?
| | Molecular Sequence Data | 4 | 2013 | 2855 | 0.130 |
Why?
| | G2 Phase | 2 | 2011 | 33 | 0.120 |
Why?
| | alpha Karyopherins | 1 | 2014 | 15 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2019 | 1048 | 0.110 |
Why?
| | Mice | 6 | 2023 | 15446 | 0.110 |
Why?
| | Mutation | 3 | 2019 | 3435 | 0.110 |
Why?
| | Vibrio parahaemolyticus | 1 | 2012 | 1 | 0.110 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 194 | 0.110 |
Why?
| | Drosophila | 1 | 2014 | 140 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1385 | 0.110 |
Why?
| | Cell Division | 2 | 2011 | 775 | 0.110 |
Why?
| | Peptides | 2 | 2023 | 879 | 0.110 |
Why?
| | Anoikis | 2 | 2023 | 34 | 0.100 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2011 | 67 | 0.100 |
Why?
| | Transient Receptor Potential Channels | 1 | 2010 | 5 | 0.100 |
Why?
| | Centrioles | 1 | 2011 | 36 | 0.100 |
Why?
| | Ion Channel Gating | 1 | 2010 | 85 | 0.090 |
Why?
| | Caffeine | 1 | 2010 | 61 | 0.090 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2011 | 111 | 0.090 |
Why?
| | Superoxide Dismutase | 1 | 2012 | 338 | 0.090 |
Why?
| | Enzyme Activation | 1 | 2012 | 810 | 0.090 |
Why?
| | RNA | 1 | 2016 | 830 | 0.090 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 275 | 0.090 |
Why?
| | Inflammation | 1 | 2020 | 2545 | 0.090 |
Why?
| | CDC2 Protein Kinase | 2 | 2010 | 27 | 0.090 |
Why?
| | Signal Transduction | 2 | 2014 | 4688 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 3 | 2012 | 650 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2011 | 360 | 0.090 |
Why?
| | Neoplasms | 1 | 2023 | 2160 | 0.090 |
Why?
| | Aurora Kinases | 1 | 2008 | 28 | 0.080 |
Why?
| | Fertilization | 1 | 2008 | 43 | 0.080 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 810 | 0.080 |
Why?
| | Centromere | 1 | 2008 | 43 | 0.080 |
Why?
| | RNA, Small Interfering | 2 | 2020 | 562 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 737 | 0.070 |
Why?
| | Prognosis | 3 | 2022 | 3425 | 0.070 |
Why?
| | MCF-7 Cells | 2 | 2017 | 110 | 0.070 |
Why?
| | Cloning, Molecular | 1 | 2008 | 541 | 0.070 |
Why?
| | Histones | 2 | 2023 | 546 | 0.070 |
Why?
| | Bacterial Proteins | 1 | 2012 | 762 | 0.070 |
Why?
| | Neoplasm Grading | 2 | 2019 | 257 | 0.070 |
Why?
| | Cell Extracts | 1 | 2006 | 17 | 0.070 |
Why?
| | Meiosis | 1 | 2006 | 61 | 0.070 |
Why?
| | Oxidative Stress | 1 | 2012 | 1167 | 0.070 |
Why?
| | Sequence Analysis, RNA | 2 | 2019 | 410 | 0.070 |
Why?
| | Anaphase-Promoting Complex-Cyclosome | 1 | 2005 | 6 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2013 | 4044 | 0.070 |
Why?
| | RNA Interference | 2 | 2019 | 459 | 0.060 |
Why?
| | 3' Untranslated Regions | 2 | 2017 | 141 | 0.060 |
Why?
| | Amino Acid Transport Systems, Neutral | 1 | 2004 | 5 | 0.060 |
Why?
| | Polycomb-Group Proteins | 1 | 2023 | 36 | 0.060 |
Why?
| | MAP Kinase Signaling System | 1 | 2005 | 284 | 0.060 |
Why?
| | Activating Transcription Factor 6 | 1 | 2023 | 17 | 0.060 |
Why?
| | DNA Primers | 2 | 2016 | 532 | 0.060 |
Why?
| | Mass Spectrometry | 2 | 2019 | 670 | 0.060 |
Why?
| | Recombinational DNA Repair | 1 | 2022 | 10 | 0.060 |
Why?
| | Homologous Recombination | 1 | 2022 | 22 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 81 | 0.050 |
Why?
| | Estrogens | 2 | 2016 | 329 | 0.050 |
Why?
| | Alternative Splicing | 1 | 2004 | 190 | 0.050 |
Why?
| | Reactive Oxygen Species | 2 | 2017 | 571 | 0.050 |
Why?
| | Base Sequence | 3 | 2012 | 2148 | 0.050 |
Why?
| | Lysine | 1 | 2023 | 247 | 0.050 |
Why?
| | Models, Biological | 1 | 2008 | 1701 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2019 | 1590 | 0.050 |
Why?
| | ErbB Receptors | 1 | 2023 | 569 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 2019 | 108 | 0.040 |
Why?
| | Protein Structure, Tertiary | 2 | 2012 | 822 | 0.040 |
Why?
| | Paracrine Communication | 1 | 2019 | 55 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2019 | 206 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 312 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 980 | 0.040 |
Why?
| | MicroRNAs | 2 | 2016 | 633 | 0.040 |
Why?
| | Apoptosis | 1 | 2008 | 2461 | 0.040 |
Why?
| | Protein Transport | 1 | 2019 | 407 | 0.040 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2019 | 192 | 0.040 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 354 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1163 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 403 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 935 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 895 | 0.040 |
Why?
| | CD146 Antigen | 1 | 2016 | 41 | 0.040 |
Why?
| | Survival Rate | 1 | 2020 | 1716 | 0.030 |
Why?
| | Gene Library | 1 | 2016 | 125 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 649 | 0.030 |
Why?
| | Tamoxifen | 1 | 2016 | 198 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1567 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2014 | 2657 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 143 | 0.030 |
Why?
| | Receptors, Steroid | 1 | 2014 | 54 | 0.030 |
Why?
| | Organisms, Genetically Modified | 1 | 2012 | 18 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2014 | 479 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 238 | 0.030 |
Why?
| | Two-Hybrid System Techniques | 1 | 2012 | 58 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2477 | 0.030 |
Why?
| | Maturation-Promoting Factor | 1 | 2012 | 3 | 0.030 |
Why?
| | Zinc Fingers | 1 | 2012 | 46 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 2012 | 67 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2019 | 2262 | 0.030 |
Why?
| | Sequence Deletion | 1 | 2012 | 169 | 0.030 |
Why?
| | Proline | 1 | 2012 | 71 | 0.030 |
Why?
| | Mitochondria | 1 | 2017 | 785 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4575 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1787 | 0.020 |
Why?
| | Microscopy, Polarization | 1 | 2011 | 33 | 0.020 |
Why?
| | Catalytic Domain | 1 | 2012 | 206 | 0.020 |
Why?
| | TRPA1 Cation Channel | 1 | 2010 | 5 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2012 | 363 | 0.020 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2010 | 18 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1482 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2010 | 100 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2012 | 283 | 0.020 |
Why?
| | Point Mutation | 1 | 2010 | 227 | 0.020 |
Why?
| | Calcium Channels | 1 | 2010 | 149 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1186 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1157 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1302 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1434 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2010 | 548 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2659 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1322 | 0.020 |
Why?
| | Cell-Free System | 1 | 2006 | 48 | 0.020 |
Why?
| | Cell Line | 1 | 2012 | 2693 | 0.020 |
Why?
| | Spermatozoa | 1 | 2006 | 91 | 0.020 |
Why?
| | Male | 2 | 2008 | 57479 | 0.020 |
Why?
| | Glycine Plasma Membrane Transport Proteins | 1 | 2004 | 8 | 0.020 |
Why?
| | Embryo, Nonmammalian | 1 | 2004 | 174 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2004 | 265 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 288 | 0.010 |
Why?
| | Calcium | 1 | 2004 | 1151 | 0.010 |
Why?
|
|
Yamamoto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|